These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 29206243)

  • 41. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
    Davis MP
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peripherally Administered Y
    Ailanen L; Vähätalo LH; Salomäki-Myftari H; Mäkelä S; Orpana W; Ruohonen ST; Savontaus E
    Front Pharmacol; 2018; 9():319. PubMed ID: 29674968
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier.
    Wu YK; Yeh CF; Ly TW; Hung MS
    Curr Top Med Chem; 2011; 11(12):1421-9. PubMed ID: 21510837
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The CB1 receptor is required for the establishment of the hyperlocomotor phenotype in developmentally-induced hypothyroidism in mice.
    Giné E; Echeverry-Alzate V; Lopez-Moreno JA; Rodriguez de Fonseca F; Perez-Castillo A; Santos A
    Neuropharmacology; 2017 Apr; 116():132-141. PubMed ID: 28017790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice.
    Hildebrandt AL; Kelly-Sullivan DM; Black SC
    Eur J Pharmacol; 2003 Feb; 462(1-3):125-32. PubMed ID: 12591104
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity.
    Argueta DA; DiPatrizio NV
    Physiol Behav; 2017 Mar; 171():32-39. PubMed ID: 28065722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future.
    Simon V; Cota D
    Eur J Endocrinol; 2017 Jun; 176(6):R309-R324. PubMed ID: 28246151
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Corrigendum: Blood brain barrier dysfunction and delayed neurological deficits in mild traumatic brain injury induced by blast shock waves.
    Shetty AK; Mishra V; Kodali M; Hattiangady B
    Front Cell Neurosci; 2014; 8():404. PubMed ID: 25501938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Hagmann WK
    Arch Pharm (Weinheim); 2008 Jul; 341(7):405-11. PubMed ID: 18574849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats.
    Rivera P; Luque-Rojas MJ; Pastor A; Blanco E; Pavón FJ; Serrano A; Crespillo A; Vida M; Grondona JM; Cifuentes M; Bermúdez-Silva FJ; de la Torre R; de Fonseca FR; Suárez J
    Eur J Neurosci; 2013 Jan; 37(1):105-17. PubMed ID: 23033907
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Corrigendum: Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke.
    Lakhan SE; Kirchgessner A; Tepper D; Leonard A
    Front Neurol; 2018; 9():202. PubMed ID: 29643832
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Corrigendum: Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models.
    Coroniti R; Farjo R; Nuno DJ; Otvos L; Scolaro L; Surmacz E
    Front Mol Biosci; 2016; 3():75. PubMed ID: 27878121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.
    Janero DR; Lindsley L; Vemuri VK; Makriyannis A
    Expert Opin Drug Discov; 2011 Oct; 6(10):995-1025. PubMed ID: 22646861
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and pharmacological characterization of functionalized 6-piperazin-1-yl-purines as cannabinoid receptor 1 (CB1) inverse agonists.
    Amato GS; Manke A; Vasukuttan V; Wiethe RW; Snyder RW; Runyon SP; Maitra R
    Bioorg Med Chem; 2018 Aug; 26(15):4518-4531. PubMed ID: 30077609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
    Laprairie RB; Kulkarni PM; Deschamps JR; Kelly MEM; Janero DR; Cascio MG; Stevenson LA; Pertwee RG; Kenakin TP; Denovan-Wright EM; Thakur GA
    ACS Chem Neurosci; 2017 Jun; 8(6):1188-1203. PubMed ID: 28103441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
    Zhu B; Matthews JM; Xia M; Black S; Chen C; Hou C; Liang Y; Tang Y; Macielag MJ
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5597-5601. PubMed ID: 27671499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cannabinoid receptor type 1 mediates high-fat diet-induced insulin resistance by increasing forkhead box O1 activity in a mouse model of obesity.
    Chen CC; Lee TY; Kwok CF; Hsu YP; Shih KC; Lin YJ; Ho LT
    Int J Mol Med; 2016 Mar; 37(3):743-54. PubMed ID: 26847930
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice.
    Lazzari P; Sanna A; Mastinu A; Cabasino S; Manca I; Pani L
    Behav Brain Res; 2011 Mar; 217(2):432-8. PubMed ID: 21074566
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice.
    Micale V; Drago F; Noerregaard PK; Elling CE; Wotjak CT
    Front Pharmacol; 2019; 10():207. PubMed ID: 30949045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blockade of Cannabinoid CB1 receptor attenuates the acquisition of morphine-induced conditioned place preference along with a downregulation of ERK, CREB phosphorylation, and BDNF expression in the nucleus accumbens and hippocampus.
    Zhang J; Wang N; Chen B; Wang Y; He J; Cai X; Zhang H; Wei S; Li S
    Neurosci Lett; 2016 Sep; 630():70-76. PubMed ID: 27461790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.